Questionnaire based survey of Psychiatrists to know their treatment options for Bipolar Disorders

Completed

Conditions: Bipolar Disorders

Registration Number: CTRI/2014/11/005213

Lead Sponsor: Glaxosmithkline Pharmaceuticals Limited

Brief Summary: Bipolar Disorder is a serious disorder of mood that is associated with considerable psychosocial and economic morbidity. Misdiagnosis of the illness as recurrent unipolar depression is common, leading to initiation of medicines that adversely affect the condition’s course. Despite their widespread use, considerable uncertainty and controversy remains about the use of antidepressant drugs in the management of depressive episodes.

There are limited data from India to suggest whether availability of newer options [atypical antipsychotics (mono/combination with mood stabilizers), antiepileptic agents (for acute mania), and psychosocial interventions for maintenance] have reflected in prescription behaviour of psychiatrists in treatment of BPD. Moreover, India specific data are missing with reference to treatment recommended in guidelines and prevailing in the clinical practice.

There is significant unmet medical need in understanding various important aspects in the management of BPD such as treatment of different phases of BPD; place of combination medications; treatment for mixed states, hypomania, rapid cycling; place of antidepressants in treating bipolar depression; use of psychological therapies and electroconvulsive therapy (ECT); etc. At present, there are scarce published data on the prevalent diagnostic and treatment practices for patients suffering from BPD among psychiatrists practicing in India. Hence, this study will be conducted to gather data on prescription patterns of psychiatrists practicing in India for acute and maintenance phases of BPD and identify gaps (if any) between guideline recommendations and treatments most frequently chosen by them.

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 500

Inclusion Criteria

1.Psychiatrists (with postgraduate degree/diploma/fellowship in psychiatry) practicing for at least 3 years after post graduation in India.
2.Psychiatrists willing to sign the consent form 3.Psychiatrists willing to complete the survey.

Exclusion Criteria

Psychiatrists practicing for fewer than 3 years after post graduation in India.
2.Psychiatrists not willing to sign the consent form 3.Psychiatrists not willing to complete the survey questionnaire.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The usage pattern of pharmacological and non-pharmacological interventions by Psychiatrists practicing in India for bipolar disorders	2 months

Secondary Outcome Measures

Name	Time	Method
1.Determination of gaps (if any) in CANMAT guidelines and treatment chosen in the clinical practice in India	2.Determination of the extent of use of antidepressants in bipolar disorder by psychiatrists practising in India

Trial Locations

Locations (1): Glaxosmithkline Pharmaceuticals Limited
🇮🇳
Mumbai, MAHARASHTRA, India
Glaxosmithkline Pharmaceuticals Limited
🇮🇳Mumbai, MAHARASHTRA, India
Dr Sujay S Kulkarni
Principal investigator
sujay.s.kulkarni@gsk.com